Triple negative breast cancer: unmet medical needs.
Triple negative breast cancer: unmet medical needs.
复制标题
DOI：
10.1007/s10549-010-1293-1
复制
发表时间：
2011-02
影响因子：
3.8
通讯作者：
Pegram, Mark
中科院分区：
文献类型：
--
作者：
Pal, Sumanta Kumar;Childs, Barrett H.;Pegram, Mark
三阴性乳腺癌（TNBC）是一种侵袭性临床表型，其特征在于缺乏雌激素受体（ER）和孕激素受体（PR）的表达（或最小表达）以及不存在人表皮生长因子受体-2（HER 2）过表达。它与基底型和BRCA 1相关的乳腺癌有很大的重叠，这两种乳腺癌也有侵袭性的临床病程。然而，这种重叠并不完全，ER、PR和HER 2的表达在基底细胞样肿瘤中已经被注意到。TNBC还包括正常样亚型，并非所有TNBC患者都携带BRCA 1突变。由于其表达谱，TNBC不适合用激素疗法或抗HER 2单克隆抗体曲妥珠单抗治疗，并且全身性治疗选择目前限于细胞毒性化疗。与具有其他表型的患者相比，无论是早期还是晚期疾病的总生存期都很差。许多针对TNBC的靶向方法正在接受临床评估，包括使用含聚乙烯的药物（ADP-核糖）聚合酶抑制特性，如iniparib（美国采用的研究药物BSI-201的名称）、奥拉帕尼（AZD 2281）和维利帕尼（ABT-888），抗血管生成药物如贝伐单抗和舒尼替尼，和表皮生长因子受体阻断剂如西妥昔单抗和埃罗替尼。已经报道了其中一些药物的令人鼓舞的结果，从而为改善TNBC患者的结局提供了希望。TNBC的临床特点和临床经验，迄今为止与新的靶向药物正在开发的这种侵略性表型进行审查。
Triple negative breast cancer (TNBC) is an aggressive clinical phenotype characterized by lack of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor–2 (HER2) overexpression. It shows substantial overlap with basal-type and BRCA1-related breast cancers, both of which also have aggressive clinical courses. However, this overlap is not complete, and the expression of ER, PR, and HER2 has been noted in basal-like tumors. TNBC also includes the normal-like subtype, and not all patients with TNBC harbor BRCA1 mutations. Because of its expression profile, TNBC is not amenable to treatment with hormone therapy or the anti-HER2 monoclonal antibody trastuzumab, and systemic treatment options are currently limited to cytotoxic chemotherapy. Overall survival, whether in early-stage or advanced disease, is poor compared with that in patients who have other phenotypes. A number of targeted approaches to TNBC are undergoing clinical evaluation, including the use of agents with poly(ADP-ribose) polymerase inhibitory properties such as iniparib (the United States Adopted Name for the investigational agent BSI-201), olaparib (AZD2281), and veliparib (ABT-888), antiangiogenic agents such as bevacizumab and sunitinib, and epidermal growth factor receptor blockers such as cetuximab and erlotinib. Encouraging results with some of these agents have been reported, thereby offering the promise for improved outcomes in patients with TNBC. The clinical characteristics of TNBC and clinical experience to date with novel targeted agents under development for this aggressive phenotype is reviewed.
登录
查看更多内容
在412例患者的基于人群的队列中，乳腺癌的固有分子特征。
影响因子：
7.4
作者：
Calza, Stefano;Hall, Per;Auer, Gert;Bjohle, Judith;Klaar, Sigrid;Kronenwett, Ulrike;T Liu, Edison;Miller, Lance;Ploner, Alexander;Smeds, Johanna;Bergh, Jonas;Pawitan, Yudi
通讯作者：
Pawitan, Yudi
DOI：
10.1186/bcr1636
发表时间：
2007
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Fulford LG;Reis-Filho JS;Ryder K;Jones C;Gillett CE;Hanby A;Easton D;Lakhani SR
通讯作者：
Lakhani SR
影响因子：
45.3
作者：
Burstein, Harold J.;Elias, Anthony D.;Miller, Kathy D.
通讯作者：
Miller, Kathy D.
DOI：
10.1073/pnas.98.1.130
发表时间：
2001-01-02
影响因子：
11.1
作者：
Beger, C;Pierce, LN;Wong-Staal, F
通讯作者：
Wong-Staal, F
影响因子：
45.3
作者：
Atchley, Deann P.;Albarracin, Constance T.;Arun, Banu K.
通讯作者：
Arun, Banu K.